97453-25-3 Usage
Uses
Used in Menopausal Syndrome Treatment:
Dehydroepiandrosterone-D5 (DHEA-D5) (2,2,3,4,4-D5) is used as an active agent in the preparation of pharmaceuticals for the treatment of menopausal syndrome. It helps in addressing the hormonal imbalances and symptoms associated with menopause.
Used in Respiratory Disease Treatment:
Dehydroepiandrosterone-D5 (DHEA-D5) (2,2,3,4,4-D5) is used as an active agent in the preparation of pharmaceuticals for the treatment of asthma or other respiratory diseases. Its potential anti-inflammatory and immunomodulatory effects make it a promising candidate for respiratory therapy.
Used in Pharmaceutical Research:
Dehydroepiandrosterone-D5 (DHEA-D5) (2,2,3,4,4-D5) is used as a labeled analogue in pharmaceutical research to study the metabolism, distribution, and effects of DHEA in the body. This helps in understanding the mechanisms of action and potential therapeutic applications of DHEA and its derivatives.
Check Digit Verification of cas no
The CAS Registry Mumber 97453-25-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,4,5 and 3 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 97453-25:
(7*9)+(6*7)+(5*4)+(4*5)+(3*3)+(2*2)+(1*5)=163
163 % 10 = 3
So 97453-25-3 is a valid CAS Registry Number.
97453-25-3Relevant academic research and scientific papers
Synthesis of Deuterium-Labelled 16α-Hydroxy-4-androstene-3,17-dione and 16α-hydroxydehydroepiandrosterone
Numazawa, Mitsuteru,Ogata, Mieko
, p. 865 - 868 (2007/10/02)
16α-Hydroxy-4-androstene-3,17-dione-d5 (4) and 3β,16α-hydroxy-5-androsten-17-one-d6 (10) were synthesized.Treatment of 16α-bromo-5-androstene-3,17-dione (2) with deuterium oxide and methanol-OD gave the 4-en-3-oxo derivative-d 3.The bromide 3 was converted into the 16α-hydroxy-d5 4 via controlled alkaline hydrolysis using sodium hydroxide-OD in deuterium oxide-pyridine. 3β-Hydroxy-5-androstene-17-one-d5 (8), which was obtained from 17,17-ethylenedioxy-5-androsten-3-one (5) via treatment with potassium tert-butoxide in tert-butanol-OD, followed by lithium aluminium tri-tert-butoxydeuteride reduction and then acid hydrolysis, was derivatized to the 16α-bromide 9 by treatment with cupric bromide.The bromide 9 was similarly hydrolyzed to yield the 16α-hydroxide-d6 10.Keywords - controlled alkaline hydrolysis; deuterium labelling; 16α-bromodehydroepiandrosterone-d5; 16α-bromoandrostenedione-d4; 16α-hydroxydehydroepiandrosterone-d6; 16α-hydroxyandrostenedione-d5.
